Accelerator mass spectrometry best practices for accuracy and precision in bioanalytical 14C measurements

Bioanalysis

Volumn 2, Issue 3, 2010, Pages 455-468

  Vogel, John S ^a   Giacomo, Jason A ^c   Schulze Knig, Tim ^b   Keck, Bradly D ^c   Lohstroh, Peter ^c   Dueker, Stephen ^c  

^a Vitalea Science   (United States)

^b ETH ZURICH   (Switzerland)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; CARBON;

ACCELERATOR MASS SPECTROMETRY; ACCURACY; COMBUSTION; DILUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG STABILITY; DRUG URINE LEVEL; HUMAN; INSTRUMENT VALIDATION; ION TRANSPORT; IONIZATION; ISOTOPE ANALYSIS; LIMIT OF QUANTITATION; MASS SPECTROMETRY; MATHEMATICAL COMPUTING; PRECIPITATION; REVIEW; ANALYSIS; CHEMISTRY; METHODOLOGY;

ANALYTIC SAMPLE PREPARATION METHODS; CARBON RADIOISOTOPES; HUMANS; MASS SPECTROMETRY;

EID: 79952471652     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.10.13     Document Type: Review

References (52)

1. Schoenheimer R, Rittenberg D. Deuterium as an indicator in the study of intermediary metabolism. J. Biol. Chem. 111, 163-168 (1935).
2. Kamen M. Tracers. Sci. Am. 180, 30-40 (1949).
3. Muller RA. Radioisotope dating with a cyclotron. Science 196, 489-494 (1977). (Pubitemid 8090462)
4. Nelson DE, Korteling RG, Stott WR. Carbon-14: direct detection at natural concentrations. Science 198, 507-508 (1977). (Pubitemid 8188133)
5. Bennett CL, Beukens RP, Clover MR et al. Radiocarbon dating using electrostatic accelerators: negative-ions provide key. Science 198, 508-510 (1977). (Pubitemid 8188134)
6. Shapiro SD, Endicott SK, Province MA, Pierce JA, Campbell EJ. Marked longevity of human lung parenchymal elastic fibers deduced from prevalence of d-aspartate and nuclear weapons-related radiocarbon. J. Clin. Invest. 87, 1828-1834 (1991).
7. Spalding KL, Bhardwaj RD, Buchholz BA, Druid H, Frisen J. Retrospective birth dating of cells in humans. Cell 122, 133-143 (2005). (Pubitemid 40977946)
8. Bhardwaj RD, Curtis MD, Spalding KL et al. Neocortical neurogenesis in humans is restricted to development. Proc. Natl Acad. Sci. USA 103, 12564-12568 (2006). (Pubitemid 44267298)
9. Spalding KL, Arner E, Westermark PO et al. Dynamics of fat cell turnover in humans. Nature 453, 783-787 (2008). (Pubitemid 351793777)
10. Vogel JS, Love AH. Quantitating isotopic molecular labels with accelerator mass spectrometery. Meth. Enzymol. 402, 402-422 (2005). (Pubitemid 43053134)
11. Mauthe RJ, Dingley KH, Leveson SH et al. Comparison of DNA-adduct and tissue-available dose levels of MeIQX in human and rodent colon following administration of a very low dose. Int. J. Cancer 80, 539-545 (1999). (Pubitemid 29047518)
12. Martin EA, Brown K, Gaskell M et al. Tamoxifen DNA damage detected in human endometrium using accelerator mass spectrometry. Cancer Res. 63, 8461-8465 (2003). (Pubitemid 37549502)
13. Gilman SD, Gee SJ, Hammock BD et al. Analytical performance of accelerator mass spectrometry and liquid scintillation counting for detection of 14C-labeled atrazine metabolites in human urine. Anal. Chem. 70, 3463-3469 (1998).
14. Vogel JS, Keating GA, Buchholz BA. Protein binding of isofluorophate in vivo after co-exposure to multiple chemicals. Environ. Health Pers. 110, 1031-1036 (2002). (Pubitemid 36204297)
15. Lin YM, Dueker SR, Follett JR et al. Quantitation of in vivo human folate metabolism. Am. J. Clin. Nutr. 80, 680-691 (2004). (Pubitemid 41115534)
16. Lappin G, Kuhnz W, Jochemsen R et al. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. Clin. Pharm. Ther. 80, 203-215 (2006). (Pubitemid 44313903)
17. Lappin G, Stevens L. Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics. Exp. Opin. Drug Metab. Tox. 4, 1021-1033 (2008).
18. Vuong L, Lohstroh P, Blood A, Vasquez H, Vogel JS. Applying AMS in neonatal research and care. J. Labeled Comp. Radiopharm. (2010).
19. Synal HA, Dobeli M, Jacob S, Stocker M, Suter M. Radiocarbon AMS towards its low-energy limits. Nuc. Instr. Meth. Phys. Res. B 223, 339-345 (2004).
20. Synal HA, Stocker M, Suter M. MICADAS: a new compact radiocarbon AMS system. Nuc. Instr. Meth. Phys. Res. B 259, 7-13 (2007). (Pubitemid 46726719)
21. Skog G The single stage AMS machine at Lund university: status report. Nuc. Instr. Meth. Phys. Res. B 259, 1-6 (2007).
22. Zoppi U, Crye J, Song Q, Arjomand A. Performance evaluation of the new AMS system at Accium biosciences. Radiocarbon 49, 173-182 (2007).
23. Schulze-K nig T, Dueker SR, Giacomo JA, Suter M, Vogel JS. BioMICADAS: compact next generation AMS system for pharmaceutical science. Nuc. Instr. Meth. Phys. Res. B DOI: 10.1016/j.nimb. 2009.10.057 (2010) (Epub ahead of print).
24. Graven HD, Guilderson TP, Keeling RF. Methods for high-precision C-14 AMS measurement of atmospheric CO2 at LLNL. Radiocarbon 49, 349-356 (2007).
25. Vogel JS, Ognibene T, Palmblad M, Reimer P. Counting statistics and ion interval density in AMS. Radiocarbon 46, 1103-1109 (2004).
26. US FDA CDER. Guidance for industry: bioanalytical method validation. UCM070107 (2001).
27. US FDA CDER, ICH. Guidance for industry: Guidance for industry: Q2 Validation of analytical procedures. UCM073384 (2005).
28. Keck BA, Dueker SR, Ognibene T, Vogel JS. Analytical validation of accelerator mass spectrometry for pharmaceutical development. Bioanalysis 2(3), 491-507 (2010).
29. Garner RC, Barker J, Flavell C et al. A validation study comparing accelerator MS and liquid scintillation counting for analysis of 14C-labelled drugs in plasma, urine and faecal extracts. J. Pharm. Biomed. Anal. 24, 197-209 (2000).
30. Motulsky H. Analyzing data with GraphPad Prism. GraphPad Software, San Diego, CA, USA (1999).
31. Brown TA, Southon JR. Corrections for contamination background in AMS C-14 measurements. Nuc. Instr. Meth. Phys. Res. B 123, 208-213 (1997).
32. Sigmund P, Winterbon KB. Small-angle multiple scattering of ions in the screened coulomb region. Nuc. Instr. Meth. 119, 541-557 (1974).
33. Middleton R. A review of ion sources for accelerator mass spectrometry. Nuc. Instr. Meth. 233, 193-199 (1984).
34. Bronk-Ramsey C, Hedges REM. Hybrid ion sources: Radiocarbon measurements from microgram to milligram. Nuc. Instr. Meth. Phys. Res. B 123, 539-545 (1997).
35. Mcintyre CP, Sylva SP, Roberts ML. Gas chromatograph-combustion system for C-14-accelerator mass spectrometry. Anal. Chem. 81, 6422-6428 (2009).
36. Prakash C, Shaffer CL, Tremaine LM, et al. Applications of liquid chromatography - accelerator mass spectrometry (LC-AMS) to evaluate the metabolic profiles of a drug candidate in human urine and plasma. Drug Metab. Lett. 1, 226-231 (2007).
37. Flarakos J, Liberman RG, Tannenbaum SR, Skipper PL. Integration of continuous-flow accelerator mass spectrometry with chromatography and mass-selective detection. Anal. Chem. 80, 5079-5085 (2008). (Pubitemid 351956318)
38. Vogel JS, Southon JR, Nelaon DE, Brown TA. Performance of catalytically condensed carbon for use in accelerator mass spectrometry. Nuc. Instr. Meth. Phys. Res. B 5, 289-293 (1984).
39. Vogel JS. Rapid production of graphite without contamination for biomedical AMS. Radiocarbon 34, 344-350 (1992).
40. Ognibene TJ, Bench G, Vogel JS, Peaslee GF, Murov S. A high-throughput method for the conversion of CO2 obtained from biochemical samples to graphite in septa-sealed vials for quantification of C-14 via accelerator mass spectrometry. Anal. Chem. 75, 2192-2196 (2003). (Pubitemid 36542364)
41. Vogel JS, Southon JR, Nelson DE. Catalyst and binder effects in the use of filamentous graphite for AMS. Nuc. Instr. Meth. Phys. Res. B 29, 50-56 (1987). (Pubitemid 18553851)
42. Xu XM, Trumbore SE, Zheng SH et al. Modifying a sealed tube zinc reduction method for preparation of AMS graphite targets: reducing background and attaining high precision. Nuc. Instr. Meth. Phys. Res. B 259, 320-329 (2007). (Pubitemid 46726770)
43. Kim SH, Kelly PB, Clifford AJ. Accelerator mass spectrometry targets of submilligram carbonaceous samples using the high-throughput Zn reduction method. Anal. Chem. 81, 5949-5954 (2009).
44. Brown TA, Nelson DE, Vogel JS, Southon JR. Improved collagen extraction by modified Longin method. Radiocarbon 30, 171-178 (1987).
45. Young GC, Corless S, Felgate CC, Colthup PV. Comparison of a 250 kv single-stage accelerator mass spectrometer with a 5 Mv tandem accelerator mass spectrometer - fitness for purpose in bioanalysis. Rap. Comm. Mass Spec. 22, 4035-4042 (2008).
46. Freeman S, Bishop P, Bryant C et al. The SUERC AMS laboratory after 3 years. Nuc. Instr. Meth. Phys. Res. B 259, 66-70 (2007). (Pubitemid 46726726)
47. Creek MR, Frantz CE, Fultz E et al. 14C AMS quantification of biomolecular interactions using microbore and plate separations. Nuc. Instr. Meth. Phys. Res. B 92, 454-458 (1994).
48. Miyashita M, Presley JM, Buchholz BA et al. Attomole level protein sequencing by Edman degradation coupled with accelerator mass spectrometry. Proc. Natl Acad. Sci. USA 98, 4403-4408 (2001). (Pubitemid 32294989)
49. Lappin G, Simpson M, Shishikura Y, Garner RC. High-performance liquid chromatography accelerator mass spectrometry: correcting for losses during analysis by internal standardization. Anal. Biochem. 378, 93-95 (2008).
50. Palmblad M, Vogel JS. Quantitation of binding, recovery and desalting efficiency of peptides and proteins in solid phase extraction micropipette tips. J. Chromatogr. B 814, 309-313 (2005). (Pubitemid 40091649)
51. US FDA CDER. Guidance for industry: safety testing of drug metabolites. UCM079266 (2008).
52. Vogel JS, Ognibene T, Bench G, Peaslee Gf. System for trapping and storing gases for subsequent chemical reduction to solids. Patent: USA 7611903 (2009).